Aims: To correct renal anemia, subcutaneous (SC) route of recombinant human erythropoietin (rhuEPO) administration has been associated with increased efficacy and decreased dose requirements, when compared with intravenous (IV) route. The effect of obesity as a potential modifier...
Open access
Research Article10.9734/BJMMR/2014/6244
We report the 1st case of severe, symptomatic hypocalcemia after denosumab (RANKL inhibitor) treatment in a peritoneal dialysis patient with secondary hyperparathyroidism and osteoporosis. A 58-year-old Caucasian female has been receiving chronic ambulatory peritoneal dialysis fo...
Open access
Research Article10.9734/BJMMR/2013/2989
Aims: To recognize the importance of considering perforation of viscus in the differential of peritonitis after upper gastrointestinal endoscopy in peritoneal dialysis patients and to address the potential benefit of antibiotic prophylaxis in PD patients undergoing upper GI proce...
Open access
Research Article10.9734/BJMMR/2013/2268